PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Conditions

• Persistent Pulmonary Hypertension of the Newborn

Eligibility Criteria

Sex

ALL

Age

N/A - 12 Months

Healthy Volunteers

Accepted

Study Details

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Key Dates

Start date

Jan 31, 2006

Status verified

Jan 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2028

Study Design

Enrollment

200 participants (estimated)

Arms

• Arm: PPHN
  Infants born at \>= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
• Arm: Control
  Randomly selected, normal healthy infants born at \>= 34 weeks gestational age and do not have PPHN

Primary Outcome Measure

To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 weeks ]

Central Contacts

• G. Ganesh Konduri, MD
  414-266-6820
  [email protected]
• Kathleen M Meskin, BSN
  414-337-7171
  [email protected]

Locations (1)

Find similar trials in Milwaukee, WI